AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05485584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rSIFN-co Nasal Spray
Description: 16 million IU (32 μg)/day; Twice daily
Study NCT05485584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Once daily
Study NCT05442957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHT
Description: BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
Study NCT05442957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
Study NCT05485584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Twice daily
Study NCT05298189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Audio-visual
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli.
Study NCT05298189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Auditory-only
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli.
Study NCT05298189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Visual-only
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli.
Study NCT05803200 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: No intervention was given as this is an observational study.
Study NCT05071079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
Study NCT05071079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
Study NCT05071079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
Study NCT05071079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
Study NCT05520346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Device for Toilet
Description: Device will be installed on toilet of patients will in hospital to measure all waste output.
Study NCT06345521 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06201247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JD123 injection
Description: JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
Study NCT04930809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study NCT06004648 — intervention group
Intervention type: PROCEDURE
Intervention: Upper extremity surgery
Description: Comparison of 2 different peripheral nerve blocks
Study NCT05201027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trifocal intraocular lens
Description: cataract extraction and implantation of a posterior chamber trifocal intraocular lens
Study NCT05147467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575
Description: APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
Study NCT05310643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks.
Study NCT05310643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
Study NCT05606081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logistic regression risk model
Description: Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
Study NCT05467475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479
Study NCT05467475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole
Study NCT05445401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-rehabilitation
Description: Triple pre-rehabilitation interventions of exercise, nutrition and psychology
Study NCT05445401 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Traditional care
Study NCT04609813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sponge cytological test
Description: Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
Study NCT05005455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab with new manufacturing process.
Description: 3mg/kg,I.V.,single dose
Study NCT05005455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab with old manufacturing process.
Description: 3mg/kg,I.V.,single dose
Study NCT05164055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
Study NCT06118151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection
Study NCT06118151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection
Study NCT06125912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dime Beauty TBT Cream
Description: Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
Study NCT06125912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Control
Description: Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
Study NCT06037642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC 0-2 years
Description: Four 1 hour meetings and homework
Study NCT06037642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waiting list
Description: Will be put on hold for four weeks
Study NCT05608382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile Phosphate Buffer Saline
Description: control group
Study NCT05608382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SGW13
Description: active comparator
Study NCT05452330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
Study NCT05452330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical massage
Description: Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
Study NCT04660526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators
Description: EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
Study NCT04660526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic bystander resuscitation instruction by 911 operators
Description: 911 operators will be able to describe how to administer CPR over the phone.
Study NCT04660526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive community training of lay people in CPR and AED use.
Description: Training of lay people regarding CPR and AED use.
Study NCT04660526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized first responder performance including earlier use of AEDs.
Description: First responders will recognize where AEDs are located and use them appropriately
Study NCT04703036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine is an amino-acid (protein)
Study NCT04703036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: This is a donor of the amino-acid cysteine (protein)
Study NCT04703036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Alanine is an amino-acid (protein)
Study NCT04822649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Adenosine stress echocardiography with the evaluation of coronary artery blood flow
Description: The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis.
Study NCT06178445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC plus trastuzumab and pembrolizumab
Description: SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
Study NCT05510154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: A single, brief advice session on switching to electronic cigarettes.
Study NCT05510154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Training
Description: A single, in-depth training session on switching to electronic cigarettes.
Study NCT05510154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to Competency
Description: Multiple, in-depth training sessions on switching to electronic cigarettes.
Study NCT04762641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL503
Description: ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study NCT02900079 — intervention group
Intervention type: DEVICE
Intervention: rapid diagnostic test for malaria antigen
Description: rapid diagnostic test for malaria antigen to be used by travelers when febrile
Study NCT05014360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablets will be administered orally.
Study NCT05058755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab, azacytidine, lenalidomide
Description: tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days.
Study NCT05058755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab, etoposide, pegaspargase
Description: tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days
Study NCT06208384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin eye drop
Description: Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Study NCT06208384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Study NCT03932656 — intervention group
Intervention type: BEHAVIORAL
Intervention: Combined schema-therapy and cognitive behavioral therapy
Description: A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
Study NCT03932656 — intervention group
Intervention type: DRUG
Intervention: Psychopharmaceuticals
Description: Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
Study NCT05794165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombate infusion
Description: Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Study NCT05794165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Study NCT06433830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
Study NCT05584670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion
Study NCT05584670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Solution for infusion
Study NCT01865630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
Study NCT05488210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: FontActiv DiaBest HP/HC
Description: Daily intake of two FontActiv DiaBest HP/HC during 2 months
Study NCT05342662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light-blocking glasses
Description: Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
Study NCT05342662 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glasses with clear lenses
Description: Non-blue light-blocking glasses
Study NCT04932850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAD0004J08
Description: Human mAb 100 mg / 2.5 mL solution for injection
Study NCT04932850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MAD0004J08 2.5 mL solution for injection
Study NCT06242379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMP compliant-BM-MSC derived sEVs
Description: The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
Study NCT05954923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino acid bolus infusion
Description: Equimolar bolus infusions of amino acids or saline (placebo)
Study NCT04912245 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth visit
Description: Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
Study NCT05726851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.
Study NCT05726851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2025 matched placebo IV infusion.
Study NCT05788887 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Authentic Ladotyri Mytilinis PDO cheese
Description: Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
Study NCT05788887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
Study NCT05097521 — intervention group
Intervention type: OTHER
Intervention: Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
Description: Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings